14-day Premium Trial Subscription Sign Up For FreeGet Free

Coherus BioSciences Stock Forecast NASDAQ:CHRS

Price Target and Analyst Ratings

Most Recent Rating

On August 06, 2021 "Maxim Group" gave "$22.00" rating for CHRS. The price target was set to $13.02+0.0%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-08-06 $22.00 Initiated by Maxim Group $13.02 $13.02+0.0%
2021-07-23 $26.00 - $36.00 Target Raised by HC Wainwright $13.07 $12.68→3.4%
2021-05-24 Overweight Target Lowered by Barclays $13.19 $28.00 → $24.00
2021-05-17 Overweight Target Lowered by Barclays $14.14 $28.00 → $24.00
2021-05-13 Buy Target Lowered by HC Wainwright $13.89 $29.00 → $26.00
2021-05-07 Buy Initiated by Maxim Group $14.32 $22.00
2021-05-07 Buy Target Lowered by HC Wainwright $14.32 $28.00 → $26.00
2021-03-03 Buy Target Lowered by HC Wainwright $15.43 $33.00 → $29.00
2021-02-25 Buy Reiterated by HC Wainwright $15.25 $33.00 → $29.00
2021-02-25 Buy Target Lowered by HC Wainwright $15.25 $33.00 → $29.00
2021-02-25 Target Lowered by Citigroup $15.25 $30.00 → $27.00
2020-11-19 Buy Target Lowered by Mizuho $17.92 $35.00 → $30.00
2020-11-06 Buy Target Lowered by HC Wainwright $16.68 $33.00 → $32.00
2020-08-07 Buy Initiated by Maxim Group $19.63 $27.00
2020-08-07 Buy Target Raised by HC Wainwright $19.63 $30.00 → $33.00
2020-07-16 Neutral Initiated by BofA Securities $18.30 $20.00
2020-07-16 Neutral Initiated by Bank of America $18.30 $20.00
2020-05-08 Buy Reiterated by HC Wainwright $17.30 $30.00
2020-04-17 Buy Initiated by SunTrust Banks $15.53 $26.00

CHRS Stock Trend

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled.

Given the current short-term trend, the stock is expected to rise 13.8% during the next 3 months and, with a 90% probability hold a price between $15.91 and $19.70 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-20 $14.01 $15.68 $17.34
2021-09-21 $14.05 $15.71 $17.38
2021-09-22 $14.08 $15.74 $17.41
2021-09-23 $14.11 $15.78 $17.44
2021-09-24 $14.15 $15.81 $17.48
2021-09-27 $14.18 $15.84 $17.51
2021-09-28 $14.21 $15.88 $17.54
2021-09-29 $14.25 $15.91 $17.58
2021-09-30 $14.28 $15.94 $17.61
2021-10-01 $14.31 $15.98 $17.64
2021-10-04 $14.35 $16.01 $17.68
2021-10-05 $14.38 $16.04 $17.71
2021-10-06 $14.41 $16.08 $17.74
2021-10-07 $14.45 $16.11 $17.78
2021-10-08 $14.48 $16.14 $17.81
2021-10-11 $14.51 $16.18 $17.84
2021-10-12 $14.55 $16.21 $17.88
2021-10-13 $14.58 $16.24 $17.91
2021-10-14 $14.61 $16.28 $17.94
2021-10-15 $14.65 $16.31 $17.98
2021-10-18 $14.68 $16.34 $18.01
2021-10-19 $14.71 $16.38 $18.04
2021-10-20 $14.75 $16.41 $18.08
2021-10-21 $14.78 $16.44 $18.11
2021-10-22 $14.81 $16.48 $18.14
2021-10-25 $14.85 $16.51 $18.17
2021-10-26 $14.88 $16.54 $18.21
2021-10-27 $14.91 $16.58 $18.24
2021-10-28 $14.95 $16.61 $18.27
2021-10-29 $14.98 $16.64 $18.31

About Coherus BioSciences

Coherus BioSciences Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the prevention of chemotherapy-induced neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in Phase III clinical trials for the treatment of rheumatoid ar... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT